RxDoctor Payments Data

Mihir Barvalia, MD

Cardiovascular Disease · El Cajon, CANPI 1568723922

Payments from drug & device makers

$176,329in general payments, 2019–2025

Across 899 payments — averaging $196.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$109K
  • Kiniksa Pharmaceuticals, Ltd.$21K
  • Kiniksa Pharmaceuticals International, PLC$7K
  • Abbott$6K
  • Edwards Lifesciences$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
  • plus $24K from 53 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Speaking & faculty fees$129,36973%
  • Grants$550%
  • Travel & lodging$18,71611%
  • Food & beverage$28,11316%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk65$108,642
Kiniksa Pharmaceuticals, Ltd.39$21,086
Kiniksa Pharmaceuticals International, PLC12$6,778
Abbott90$6,122
Edwards Lifesciences74$5,856
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)31$4,246
Medtronic(2 entities)73$4,176
Chiesi USA, Inc.15$3,642
Scpharmaceuticals Inc.14$2,481
Abiomed26$1,738
Novartis67$1,268
Boston Scientific34$1,122
Cvrx, Inc.45$872
Cardiovascular Systems Inc.26$853
AstraZeneca34$668
Bayer31$647
Alnylam Pharmaceuticals Inc.24$424
Inari Medical, Inc.13$416
Bard Peripheral Vascular, Inc.7$403
Actelion Pharmaceuticals US, Inc.18$327
E.r. Squibb & Sons, L.L.C.18$311
Johnson & Johnson19$304
Heartflow, Inc.5$303
Biotronik Inc.10$302
Pfizer12$247
Kestra Medical Technology Services, Inc.7$239
Shockwave Medical, Inc4$230
Angiodynamics, Inc.2$227
Reflow Medical Inc5$214
Impulse Dynamics (USA) Inc.7$202
Merck8$201
Boehringer Ingelheim9$197
KCI USA, Inc.1$163
Amgen8$125
Irhythm Technologies, Inc.2$121
Asahi Intecc USA, Inc.1$91
Philips North America LLC3$91
Jenavalve Technology, Inc.2$90
Getinge USA Sales, LLC4$89
Endologix LLC1$83
Regeneron Healthcare Solutions, Inc.4$80
Cardiva Medical, Inc.3$75
Cardinal Health 200 LLC1$69
Amryt Pharma Holdings Ltd3$67
Lexicon Pharmaceuticals, Inc.3$60
Amarin Pharma, Inc.3$59
Sanofi-aventis U.S. LLC2$44
Venclose Inc.1$43
Argon Medical Devices, Inc.1$37
Cordis US CORP.2$31
United Therapeutics Corporation2$29
Stryker1$26
Tactile Systems Technology Inc1$20
Bristol Myers Squibb1$19
Teleflex LLC1$19
Lilly USA, LLC1$17
Esperion Therapeutics, Inc.1$14
Coala Life Inc1$13
Penumbra, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$176,329 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$397,613
Medicare patients
799
Services billed
3,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$121,989
EntrestoSacubitril/Valsartan96$110,375
BrilintaTicagrelor85$56,957
OzempicSemaglutide51$54,475
JardianceEmpagliflozin50$53,301
XareltoRivaroxaban56$45,867
FarxigaDapagliflozin Propanediol41$36,488
Bydureon BciseExenatide Microspheres11$8,913
Prasugrel Hcl15$2,553
Rosuvastatin Calcium94$2,065
Metoprolol Succinate111$1,601
Atorvastatin Calcium97$1,024
Losartan Potassium108$996
Flecainide Acetate12$874
ClopidogrelClopidogrel Bisulfate74$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$247$121,989134 claims
NovartisEntresto$1,268$110,37596 claims
AstraZenecaBrilinta, Farxiga$668$93,445126 claims
Novo NordiskOzempic$108,642$54,47551 claims
Boehringer IngelheimJardiance$197$53,30150 claims
Johnson & JohnsonXarelto$304$45,86756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →